![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EIF2AK3 |
Gene summary for EIF2AK3 |
![]() |
Gene information | Species | Human | Gene symbol | EIF2AK3 | Gene ID | 9451 |
Gene name | eukaryotic translation initiation factor 2 alpha kinase 3 | |
Gene Alias | PEK | |
Cytomap | 2p11.2 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | E7ER02 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9451 | EIF2AK3 | 047563_1562-all-cells | Human | Prostate | BPH | 5.52e-18 | 6.48e-01 | 0.0791 |
9451 | EIF2AK3 | 048752_1579-all-cells | Human | Prostate | BPH | 2.73e-40 | 7.53e-01 | 0.1008 |
9451 | EIF2AK3 | 052095_1628-all-cells | Human | Prostate | BPH | 1.50e-15 | 4.31e-01 | 0.1032 |
9451 | EIF2AK3 | 052097_1595-all-cells | Human | Prostate | BPH | 4.99e-55 | 9.17e-01 | 0.0972 |
9451 | EIF2AK3 | 052099_1652-all-cells | Human | Prostate | BPH | 3.84e-29 | 6.23e-01 | 0.1038 |
9451 | EIF2AK3 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.20e-05 | 4.42e-01 | 0.1633 |
9451 | EIF2AK3 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 6.91e-03 | 3.80e-01 | 0.1621 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:000641718 | Prostate | BPH | regulation of translation | 157/3107 | 468/18723 | 9.09e-20 | 5.63e-17 | 157 |
GO:009719318 | Prostate | BPH | intrinsic apoptotic signaling pathway | 110/3107 | 288/18723 | 7.36e-19 | 2.85e-16 | 110 |
GO:000641316 | Prostate | BPH | translational initiation | 59/3107 | 118/18723 | 4.78e-17 | 1.14e-14 | 59 |
GO:003497618 | Prostate | BPH | response to endoplasmic reticulum stress | 95/3107 | 256/18723 | 1.54e-15 | 2.52e-13 | 95 |
GO:200124218 | Prostate | BPH | regulation of intrinsic apoptotic signaling pathway | 70/3107 | 164/18723 | 2.34e-15 | 3.72e-13 | 70 |
GO:000698618 | Prostate | BPH | response to unfolded protein | 61/3107 | 137/18723 | 1.40e-14 | 1.80e-12 | 61 |
GO:190382918 | Prostate | BPH | positive regulation of cellular protein localization | 98/3107 | 276/18723 | 1.46e-14 | 1.84e-12 | 98 |
GO:004586218 | Prostate | BPH | positive regulation of proteolysis | 121/3107 | 372/18723 | 2.05e-14 | 2.44e-12 | 121 |
GO:003596618 | Prostate | BPH | response to topologically incorrect protein | 66/3107 | 159/18723 | 7.35e-14 | 7.98e-12 | 66 |
GO:006219718 | Prostate | BPH | cellular response to chemical stress | 110/3107 | 337/18723 | 2.44e-13 | 2.40e-11 | 110 |
GO:003450410 | Prostate | BPH | protein localization to nucleus | 98/3107 | 290/18723 | 4.78e-13 | 4.35e-11 | 98 |
GO:007149618 | Prostate | BPH | cellular response to external stimulus | 102/3107 | 320/18723 | 8.99e-12 | 6.79e-10 | 102 |
GO:00064468 | Prostate | BPH | regulation of translational initiation | 39/3107 | 79/18723 | 1.57e-11 | 1.13e-09 | 39 |
GO:005254718 | Prostate | BPH | regulation of peptidase activity | 133/3107 | 461/18723 | 2.08e-11 | 1.43e-09 | 133 |
GO:190018010 | Prostate | BPH | regulation of protein localization to nucleus | 54/3107 | 136/18723 | 1.02e-10 | 6.02e-09 | 54 |
GO:003462017 | Prostate | BPH | cellular response to unfolded protein | 42/3107 | 96/18723 | 3.43e-10 | 1.81e-08 | 42 |
GO:004328118 | Prostate | BPH | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 71/3107 | 209/18723 | 5.88e-10 | 2.89e-08 | 71 |
GO:19001829 | Prostate | BPH | positive regulation of protein localization to nucleus | 39/3107 | 87/18723 | 6.07e-10 | 2.91e-08 | 39 |
GO:005254818 | Prostate | BPH | regulation of endopeptidase activity | 122/3107 | 432/18723 | 6.10e-10 | 2.91e-08 | 122 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501228 | Prostate | BPH | Parkinson disease | 143/1718 | 266/8465 | 1.19e-34 | 3.94e-32 | 2.44e-32 | 143 |
hsa0502026 | Prostate | BPH | Prion disease | 141/1718 | 273/8465 | 1.11e-31 | 1.23e-29 | 7.58e-30 | 141 |
hsa0414128 | Prostate | BPH | Protein processing in endoplasmic reticulum | 97/1718 | 174/8465 | 2.37e-25 | 1.30e-23 | 8.07e-24 | 97 |
hsa0501026 | Prostate | BPH | Alzheimer disease | 165/1718 | 384/8465 | 4.03e-25 | 1.66e-23 | 1.03e-23 | 165 |
hsa0501426 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa0493226 | Prostate | BPH | Non-alcoholic fatty liver disease | 83/1718 | 155/8465 | 2.49e-20 | 6.32e-19 | 3.91e-19 | 83 |
hsa0502226 | Prostate | BPH | Pathways of neurodegeneration - multiple diseases | 180/1718 | 476/8465 | 7.70e-20 | 1.81e-18 | 1.12e-18 | 180 |
hsa0421016 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
hsa0541728 | Prostate | BPH | Lipid and atherosclerosis | 66/1718 | 215/8465 | 1.68e-04 | 9.56e-04 | 5.92e-04 | 66 |
hsa0413726 | Prostate | BPH | Mitophagy - animal | 28/1718 | 72/8465 | 2.12e-04 | 1.13e-03 | 6.98e-04 | 28 |
hsa051607 | Prostate | BPH | Hepatitis C | 48/1718 | 157/8465 | 1.36e-03 | 5.85e-03 | 3.62e-03 | 48 |
hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
hsa041408 | Prostate | BPH | Autophagy - animal | 42/1718 | 141/8465 | 4.46e-03 | 1.53e-02 | 9.49e-03 | 42 |
hsa05012112 | Prostate | BPH | Parkinson disease | 143/1718 | 266/8465 | 1.19e-34 | 3.94e-32 | 2.44e-32 | 143 |
hsa05020111 | Prostate | BPH | Prion disease | 141/1718 | 273/8465 | 1.11e-31 | 1.23e-29 | 7.58e-30 | 141 |
hsa04141112 | Prostate | BPH | Protein processing in endoplasmic reticulum | 97/1718 | 174/8465 | 2.37e-25 | 1.30e-23 | 8.07e-24 | 97 |
hsa05010111 | Prostate | BPH | Alzheimer disease | 165/1718 | 384/8465 | 4.03e-25 | 1.66e-23 | 1.03e-23 | 165 |
hsa05014111 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa04932111 | Prostate | BPH | Non-alcoholic fatty liver disease | 83/1718 | 155/8465 | 2.49e-20 | 6.32e-19 | 3.91e-19 | 83 |
hsa05022111 | Prostate | BPH | Pathways of neurodegeneration - multiple diseases | 180/1718 | 476/8465 | 7.70e-20 | 1.81e-18 | 1.12e-18 | 180 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF2AK3 | SNV | Missense_Mutation | c.3178C>A | p.Pro1060Thr | p.P1060T | Q9NZJ5 | protein_coding | tolerated(0.46) | benign(0.406) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | c.1541N>T | p.Asp514Val | p.D514V | Q9NZJ5 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | rs770192517 | c.1873N>T | p.Arg625Cys | p.R625C | Q9NZJ5 | protein_coding | tolerated(0.1) | probably_damaging(0.98) | TCGA-BR-8059-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
EIF2AK3 | SNV | Missense_Mutation | c.1290N>C | p.Lys430Asn | p.K430N | Q9NZJ5 | protein_coding | tolerated(0.1) | possibly_damaging(0.722) | TCGA-BR-A4PD-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | c.1606N>G | p.Thr536Ala | p.T536A | Q9NZJ5 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | c.2114N>A | p.Thr705Lys | p.T705K | Q9NZJ5 | protein_coding | tolerated(0.66) | benign(0.214) | TCGA-D7-6528-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | novel | c.1552C>G | p.Leu518Val | p.L518V | Q9NZJ5 | protein_coding | tolerated(0.16) | probably_damaging(0.991) | TCGA-D7-A74A-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EIF2AK3 | SNV | Missense_Mutation | c.1930N>A | p.Ala644Thr | p.A644T | Q9NZJ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-F1-6177-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
EIF2AK3 | SNV | Missense_Mutation | c.815N>C | p.Met272Thr | p.M272T | Q9NZJ5 | protein_coding | tolerated_low_confidence(0.35) | benign(0) | TCGA-HU-8604-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | doxifluridine | SD | |
EIF2AK3 | SNV | Missense_Mutation | novel | c.1022N>G | p.Ser341Cys | p.S341C | Q9NZJ5 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-IN-A6RJ-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Indoline derivative 7 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 336446930 | ||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Indoline derivative 3 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Phenylpyrrolidinone derivative 1 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Tricyclic isoxazoloquinazoline derivative 3 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Indoline derivative 8 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Tricyclic isoxazoloquinazoline derivative 1 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 178103351 | CHEMBL2171124 | |
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Phenylpyrrolidinone derivative 5 | |||
9451 | EIF2AK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | Indoline derivative 10 |
Page: 1 2 |